68-2

33/110

Before PSMFCV (n = 63)AMNV (n = 87)62.3±14.3M, 33 (37.9)F, 54 (62.1)12 (13.8)17 (19.5)21 (24.1)2 (2.3)V, 29 (33.3)C, 14 (16.1)TU, 14(16.1)TL, 11 (12.6)L, 10 (11.5)S, 9 (10.3)26 (29.9)2 (1, 3)2 (1, 3)1 (0, 3)0 (0, 1)11 (12.6)After PSMFCV (n = 52)AMNV (n = 52)65.6±13.4M, 23 (44.2)F, 29 (55.8)66.1±17.8M, 24 (46.2)F, 28 (53.8)6 (11.5)3 (5.8)7 (13.5)2 (3.8)V, 20 (38.5)C, 4 (7.7)TU, 9 (17.3)TL, 7 (13.5)L, 6 (11.5)S, 6 (11.5)V, 15 (28.8)C, 7 (13.5)TU, 17 (32.7)TL, 9 (17.3)L, 2 (3.8)S, 2 (3.8)8 (15.4)2 (1, 4)2.5 (1, 4)2 (0, 3.5)0 (0, 2)13 (25.0)2 (0.5, 2)2 (1, 3)1 (0, 3)0 (0, 1)8 (15.4)Figure 4　Comparison between numerical rating scale (NRS) pain scores in 108 propensity score-matched pairs of early visitors receiving treatment within 3 days after onset and late visitors receiving treatment later than 3 daysData are expressed as box and whisker plots. A solid line in the box depicts the median. Ends of the box represent the 75th and 25th percentiles. Whiskers represent the 90th and 10th percentiles. * Significant difference between patientsTable 4　Comparisons of clinical characteristics and primary/secondary clinical outcomes between patients treated with AMNV and patients treated with FCV within early visitors before and after propensity score matching (PSM)VariablesAntiherpetic agents (n)Clinical characteristicsAge (years)Sex; Males and FemalesAntibiotic therapySteroid userImmunocompromised stateAntidepressant userRash locationsPrimary clinical outcomesRequirements of NSAIDsNRS pain score at Day 0NRS pain score at Day 3-4NRS pain score at Day 7NRS pain score at Week 2-3Secondary clinical outcomesPHNData are shown as Mean ± SD, Median (Interquartile Range), or Number (%), and compared between patients with unpaired t test, Mann-Whitney U test, or Pearson’s chi-square test.PSM, propensity score matching; AMNV, amenamevir; FCV, famciclovir; M, males; F, females; V, trigeminal; C, cervical; TU, upper thoracic (T1-8); TL, lower thoracic (T9-12); L, lumbar; S, sacral; NSAIDs, non-steroidal anti-inflammatory drugs; NRS, numerical rating scale; PHN, postherpetic neuralgia p values0.0237 68.2±17.1M, 30 (47.6)F, 33 (52.4)0.2354 6 (9.5)5 (7.9)8 (12.7)5 (7.9)0.4271 0.0474 0.0799 0.1062 V, 18 (28.6)C, 9 (14.3)TU, 19 (30.2)TL, 10 (15.9)0.2619 L, 3 (4.8)S, 4 (6.3)10 (15.9)2 (1, 4)2 (1, 4)2 (0, 4)0 (0, 2.5)0.0473 0.3267 0.3992 0.3535 0.6190 6 (9.5)0.5519within early visitors. In early visitors, AMNV-treated patients were younger and included more steroid users than FCV-treated patients (p = 0.0237 and p = 0.0474, respectively) (Table 4), while pain scores during the acute HZ period or the inci-dence of PHN did not differ between AMNV- and FCV-treated patients, although requirements of NSAIDs were more in AMNV-treated than FCV- treated patients (p = 0.0473) (Table 4). In 52 PSM pairs in early visitors with comparable clinical characteristics, these primary or secondary clinical outcomes, including requirements of NSAIDs, did not differ between AMNV- and FCV-treated patients (Table 4).Comparison between AMNV and FCV in late visitorsForth, we performed the second subgroup anal-ysis by comparing primary/secondary clinical outcomes between 56 AMNV-treated patients and 68 FCV-treated patients within late visitors. In late p values0.87170.8438 5 (9.6)5 (9.6)7 (13.5)2 (3.8)0.7498 0.7155 1.0000 1.0000 0.1433 0.2220 0.1770 0.2361 0.3293 0.6817 5 (9.6)0.3737 125